Forbion Growth Opportunities Fund
Naarden, North Hollandforbion.com
Overview
A series of late-stage life sciences investment funds managed by Forbion. The funds focus on providing private growth capital, pre-IPO/crossover funding, and capital for undervalued public companies in the European and North American biopharmaceutical sector. The series includes Fund I (€360M, 2021 close), Fund II (€600M, 2023 close), and Fund III (€1.2B, 2024 raise).
Portfolio Companies
4
Website
forbion.comInvestments
| Company | Date | Stage | Lead |
|---|---|---|---|
| Azafaros | May 2025 | Series B | Lead |
| AIRNA | Apr 2025 | Series B | Lead |
| CatalYm | Jul 2024 | Series D | Co-investor |
| VectorY Therapeutics | Nov 2023 | Series A | Lead |
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.